Oncocyte promotes James Liu to VP Accounting, Controller, Treasurer; grants RSUs to executives

Insight Molecular Diagnostics Inc.

James Liu promoted to VP Accounting, Controller, Treasurer and Principal Accounting Officer, effective March 10, 2025; salary $225,000.
CEO Joshua Riggs annual salary raised to $420,000 from $400,000; CFO Andrea James to $341,250 from $325,000.
One-time RSU grants: CEO $600k (max 200k shares), CFO $360k (max 120k), CSO $360k (max 120k), vesting over 4 years.
CFO Andrea James receives $25,000 one-time bonus in cash or RSUs at her discretion.
James Liu also receives $60k in RSUs (3-year vest) and 10,000 options (4-year vest).

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

James Liu

Vice President Accounting, Controller, Treasurer and Principal Accounting Officer

IMDX · Insight Molecular Diagnostics Inc.

Effective: 2025-03-10
Filed: March 10, 2025, 7:59 PM ET

On March 4, 2025, the Company promoted James Liu to Vice President Accounting, Controller, Treasurer and Principal Accounting Officer, effective March 10, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James Liu changed role as Vice President Accounting, Controller, Treasurer and Principal Accounting Officer at Insight Molecular Diagnostics Inc..

Action: promoted
Role: Vice President Accounting, Controller, Treasurer and Principal Accounting Officer

Exact text from the filing

On March 4, 2025, the Company promoted James Liu to Vice President Accounting, Controller, Treasurer and Principal Accounting Officer, effective March 10, 2025.

View on SEC.gov

Insight Molecular Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-009684

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.